; and (2) beginning as soon as feasible after the development of such strategy, and not later than 5 years after the development of such strategy, implement such strategy. (b) Contents The strategy under subsection (a) shall— (1) be consistent with all applicable Federal law; (2) identify essential components, including key starting materials, active ingredients, and critical inputs, necessary for manufacturing the essential medicines and medical countermeasures published on October 30, 2020, by the Food and Drug Administration in accordance with Executive Order 13944; and (3) address the capacity of the supply chain and industrial base to strengthen and mobilize the Public Health Industrial Base to increase the manufacture in the United States of essential medicines, medical countermeasures, and critical inputs. (c) Definitions In this section: (1) The term critical inputs means active pharmaceutical ingredients, active pharmaceutical ingredient starting material, and other ingredients of drugs and components of medical devices that the Commissioner of Food and Drugs determines to be critical in assessing the safety and effectiveness of essential medicines and medical countermeasures. (2) The term essential medicine means medicine— (A) that is needed to protect the American public at all times, including from outbreaks of emerging infectious diseases, such as COVID–19, as well as chemical, biological, radiological, and nuclear threats; and (B) of which sufficient and reliable, long-term domestic production of these products, mostly generic drugs, their active pharmaceutical ingredients, and key starting materials, is needed to minimize potential shortages by reducing the Nation’s dependence on foreign manufacturers of these products. (3) The term medical countermeasure means— (A) a qualified countermeasure (as defined in section 319F–1 of the Public Health Service Act ( 42 U.S.C. 247d–6a )); (B) a qualified pandemic or epidemic product (as defined in section 319F–3 of such Act ( 42 U.S.C. 247d–6d ))